Bratislava Statement: consensus recommendations for improving pancreatic cancer care. by Prades, Joan et al.
  1Prades J, et al. ESMO Open 2020;5:e001051. doi:10.1136/esmoopen-2020-001051
Open access 
Bratislava Statement: consensus 
recommendations for improving 
pancreatic cancer care
Joan Prades   ,1,2 Dirk Arnold,3,4 Thomas Brunner,5,6 Antonella Cardone,7,8 
Alfredo Carrato   ,7,9 Cristina Coll- Ortega,1 Samuel De Luze,10 Pascal Garel,11 
Maria E Goossens,12 Roberto Grilli,13 Meggan Harris,14 Marleen Louagie,15 
Núria Malats,7,16 Pamela Minicozzi,17,18 Stefano Partelli,19,20 Silvia Pastorekova,21 
Marius Petrulionis,22,23 Richard Price,24 Francesco Sclafani   ,25,26 
Bozena Smolkova,21 Josep M Borras   1,27 
Review
To cite: Prades J, Arnold D, 




cancer care. ESMO Open 
2020;5:e001051. doi:10.1136/
esmoopen-2020-001051
Received 15 September 2020
Accepted 7 October 2020
For numbered affiliations see 
end of article.
Correspondence to
Professor Joan Prades;  
 jlprades@ iconcologia. net
© Author (s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. Published 
by BMJ on behalf of the 
European Society for Medical 
Oncology.
ABSTRACT
Pancreatic cancer is one of the most lethal tumours, and 
it is the fourth cause of cancer death in Europe. Despite 
its important public health impact, no effective treatments 
exist, nor are there high- visibility research efforts to 
improve care. This alarming situation is emblematic of 
a larger group of cancer diseases, known as neglected 
cancers. To address the impact of these diseases, the 
European Commission- supported Innovative Partnership 
for Action Against Cancer launched a multi- stakeholder 
initiative to determine key steps that healthcare systems 
can rapidly implement to improve their response. A 
working group comprising 20 representatives from 
European medical societies, patient associations, cancer 
plan organisations and other relevant European healthcare 
stakeholders was organised. A consensus process based 
on the results of different studies, discussion of research 
outcomes, and development and endorsement of draft 
statements resulted in 22 consensus recommendations 
(the Bratislava Statement). The statement argues that 
substantial improvements can be achieved in patient 
outcomes by centralising pancreatic cancer care around 
state- of- the- art reference centres, staffed by expert 
multidisciplinary teams capable of providing high- quality 
care. This organisational model requires a specific 
care framework encompassing primary, palliative and 
survivorship care, and a policy environment prioritising 
the use of quality criteria and performance assessments 
as well as research investments dedicated to prevention, 
risk prediction, early detection and diagnosis. In order 
to address the challenges posed by neglected cancers 
in general and pancreatic cancer in particular, a specific 
control strategy tailored to this reality is required.
INTRODUCTION
Pancreatic cancer is one of the most lethal 
tumours, killing about 92% of patients within 
5 years of their diagnosis.1 It is the fourth cause 
of cancer death in Europe,2–5 taking the lives 
of approximately 128 000 Europeans in 2018, 
while another 132 600 were diagnosed.2 This 
alarming situation is not unique to pancreatic 
cancer; rather, it is emblematic of a larger group 
of cancer diseases, which all have an important 
public health impact but no effective treat-
ments or high- visibility research efforts.
Acknowledging the relevance of this 
phenomenon, the European Commission- 
supported Innovative Partnership for Action 
Against Cancer6 launched a multi- stakeholder 
initiative to determine key steps that healthcare 
systems can rapidly implement to address its 
impact while maximising the value of health-
care resources. This set the groundwork for 
prioritising pancreatic cancer as well as other 
neglected cancers at the national and Euro-
pean level. Neglected cancers are defined as 
non- rare cancers with moderate incidence (<20 
per 100 000 person- year), a high mortality/
incidence ratio (≥0.7) and low survival (rela-
tive survival ≤40% at 1 year and ≤30% at 3 or 5 
years after diagnosis), due to either biological 
aggressiveness, late diagnosis or lack of effec-
tive treatments.7 In so doing, the European 
Commission has opened the door to delin-
eating a policy arena concerned specifically 
with neglected cancers, which—like common 
and rare cancers—would need to be addressed 
through a comprehensive strategy.
This initiative (the Bratislava Statement) 
resulted in consensus recommendations that 
acknowledge the importance of placing refer-
ence centres capable of providing high- quality 
care on the front lines of managing patients 
with pancreatic cancer. Reference centres 
consist of units, hospitals or even provider 
networks with a specialised multidisciplinary 
team (MDT).8 A general breakdown of the 
rationale for developing the Bratislava State-
ment is shown in box 1.
The present statement, formulated at the 
European level, summarises these comple-
mentary perspectives, indicating evidence- 
based institutional policies and measures that 
Published online 
13 November 2020 
Open access
2 Prades J, et al. ESMO Open 2020;5:e001051. doi:10.1136/esmoopen-2020-001051
policymakers, professionals and patients can promote and 
support in their efforts to optimise diagnosis, treatment and 
research in pancreatic cancer in their respective states and 
regions.
METHODS
A working group comprising representatives from medical 
societies, patient associations, cancer plan organisations 
and other relevant European healthcare stakeholders 
was organised. In representation of their institutions, 
participants took part in a consensus process based on the 
results of different studies, discussion of research outcomes, 
and development and endorsement of draft statements.
The initial research component comprised two system-
atic reviews. The first focused on the evidence on existing 
strategies and policy tools for improving access to expert 
care for patients with pancreatic cancer,9 and it identified 
three overarching health policy strategies used alone or 
in combination to increase quality of care and patients’ 
access to specialised centres. Strategies included centralisa-
tion of pancreatic surgery, external assessment of clinical 
results, and accreditation of centres and professionals. The 
second review analysed population- based data on the inci-
dence, mortality and survival of solid cancers, in order to 
create a list of neglected cancers and quantify their health 
impact. While the list includes tumours of the gallbladder 
and biliary tract, stomach, liver, brain and central nervous 
system, the most representative is pancreatic cancer, as it 
has the highest mortality/incidence ratio and the lowest 
survival.7
The central discussion took place during a meeting in 
Bratislava on 16–17 September 2019 and involved high- 
level representatives from all key stakeholder groups, 
including four national cancer plan organisations. Five 
key domains for improving the quality of care and patient 
access to specialised teams in pancreatic cancer were iden-
tified: (a) reorganisation of services and coordination of 
care; (b) reinforcement of the internal structure of centres, 
care processes and proven expertise; (c) implementation 
of external quality assessment and feedback; (d) research; 
and (e) optimisation of the role of patient organisations, 
scientific societies and European stakeholders.
The working group formulated an overarching policy 
statement (the Bratislava Statement) to define critical 
recommendations for healthcare systems in relation to the 
implementation of new approaches to improve pancreatic 
cancer care. The initial draft was then widely circulated 
among participating professionals and organisations for 
final approval.
RESULTS
Consensus recommendations for improving pancreatic cancer 
care
The following recommendations reflect the expert 
consensus on improving pancreatic cancer care along the 
five areas (a–e) identified. The first 17 recommendations 
are targeted specifically to policymakers and healthcare 
system planners, while the last 5 relate to actions that 
scientific societies, patient groups and other advocacy 
organisations can take directly.
A. Reorganisation of pancreatic cancer services and coordination 
of care
Statement 1. Implement integrated healthcare policies that 
promote specialisation and put expert MDTs at the centre of the 
decision-making process.
The complexity of managing and operating on pancreatic 
cancer, together with its relatively low incidence, justifies 
Box 1 Rationale for developing the Bratislava Statement
 ► Pancreatic cancer is comparably lethal worldwide, with most re-
ported variations in outcome attributable to the quality of data rath-
er than the quality of care.12 However, in Europe it has a relatively 
high—and rising—incidence compared with other regions.13 14 And 
despite a few improvements in treatment in recent years, mortality 
remains very high, with survival standing at 8% or less at 5 years. 
This is mainly due to the advanced stage of most tumours at diag-
nosis, which in turn stems from the late and non- specific symptom-
atology and the lack of any effective screening tests.15
 ► Pancreatic surgery plus perioperative therapy (current standard of 
care: adjuvant chemotherapy) is the only potentially curative treat-
ment, but just 20% of patients—at most—are candidates for this 
approach.3 4 Furthermore, pancreatic surgery is among the most 
technically complex and risky interventions that a patient can 
undergo.
 ► Improving the poor prognosis of neglected cancers like pancreatic 
cancer requires urgent efforts in prevention, risk prediction and ear-
ly detection, but there is scarce evidence on effective interventions 
in these areas. Thus, patients’ best hope in the short to medium 
term resides in accessing diagnostic procedures and treatment, 
provided by experienced healthcare professionals in well- equipped 
reference centres.16–18 Such measures require strategic changes 
in care processes at the healthcare system level, including in the 
development and implementation of cancer plans. For instance, 
evidence has increasingly accumulated suggesting that centres 
performing more surgeries with a curative intent achieve better 
perioperative outcomes.19
 ► While making changes in the administration of care processes is 
anything but straightforward, European scientific societies are in-
creasingly calling for just that, supplementing traditional clinical 
practice guidelines (including from such representative bodies as 
the European Society for Medical Oncology20), with recommenda-
tions on the organisation of healthcare services. For example, a 
prominent group of European surgical oncologists argue that pure 
market- driven approaches are harmful to both patients and society, 
and they propose implementing centralisation strategies to improve 
patient outcomes.21 These statements have been echoed by numer-
ous pancreatic surgical oncologists.16 17 22
 ► Likewise, and in line with the European health policy principle of 
developing a multidisciplinary cancer care model,8 the European 
CanCer Organisation (ECCO) has launched the ‘Essential require-
ments for quality cancer care’ initiative, which highlights the key 
role of expert MDTs and units in the management of patients with 
cancer.10 The health system neglect of pancreatic cancer is so strik-
ing, in fact, that a multi- stakeholder platform, Pancreatic Cancer 
Europe,23 has been established at European level to advocate for 
increased research and improvements in all areas of care.
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the consolidation of expertise within specialised MDTs or 
units. Such organisational changes are currently among 
the most effective interventions for improving patient 
outcomes and optimising the use of healthcare resources.
Statement 2. Identify reference centres and build around these 
efficient models of centralised care.
While surgical outcomes and especially surgical volume 
(pancreatectomies/year) are the most frequently studied 
measure of quality of care in pancreatic cancer, only a 
minority of patients undergo resection. Therefore, when 
identifying the centres providing the best care, a range of 
other domains should be taken into account, including 
referral pathways, diagnostic procedures, indications for 
and administration of medical (systemic) treatments, 
early integration of palliative care, research output and 
participation in clinical trials, among others.
Statement 3. Shape national or regional care models to allow 
alignment with international quality criteria.
Rigorous quality criteria, whether developed by a single 
health system or adapted from international guidance, 
are a prerequisite for ensuring high- quality care and 
should lead to a redistribution of cases towards reference 
centres. ECCO Essential Requirements for Quality Cancer 
Care are one set of criteria that recognise the need for a 
multifaceted perspective, providing national and regional 
health authorities with a valuable tool to define the char-
acteristics of reference centres.10
Statement 4. Create policy levers to ensure the adherence of non-
specialised providers to established referral pathways.
Healthcare systems may use different mechanisms to 
endow expert MDTs with the mandate to lead clinical 
decision- making processes (eg, designation of providers, 
minimum surgical volumes, publication of surgical 
outcomes). However, poor adherence among non- 
specialised providers to optimal referral pathways can 
pose challenges to achieving system objectives. Different 
policy tools can favour effective change: establishing some 
degree of legal enforcement to consolidate such a policy; 
incorporating financial incentives and/or disincentives 
for the centres; and allowing a transition period before 
full adoption of the policy.
Statement 5. Allocate enough resources to reference centres to 
support implementation of reorganisation strategies and facilitate 
an orderly transition of patients between institutions, regions and 
countries.
Designating reference centres in pancreatic cancer 
produces a net benefit for both patients (better 
outcomes) and healthcare systems (more efficient use of 
resources). However, redirecting patient flows to these 
centres can also increase the pressure to service providers 
and introduce geographical access barriers, resulting in 
patient selection biases, whereby certain patient groups—
like those with better health or socioeconomic status—
are most likely to have access to specialist care. This can 
increase the ‘financial toxicity’ of this cancer for patients. 
Moreover, newly designated pancreatic cancer care units 
may not have all the tools or training needed to rapidly 
align their practices with ever evolving state- of- the- art 
clinical practice guidelines. To fully take advantage of the 
potential benefits of this model, healthcare authorities 
should work to support reference centres to absorb the 
impacts that these organisational changes produce.
Statement 6. Create and/or strengthen networks between 
reference centres and other providers in order to improve 
continuity of care, circulation of knowledge and integration among 
professionals.
Even if most patients are referred to reference centres, 
non- specialised hospitals and other providers will continue 
to play an important role in the clinical management of 
some patients, for example those presenting to the outpa-
tient clinics or emergency departments of non- reference 
centres without a confirmed diagnosis of pancreatic 
cancer, those experiencing tumour- related or treatment- 
related complications, patients refusing referral (often 
due to old age or numerous comorbidities), and those 
who receive follow- up and after- care, including chemo-
therapy, close to home. Nurturing both formal and 
informal links between providers with different levels of 
specialisation can help to ensure better outcomes even 
for those who are managed in non- reference centres.
Statement 7. Articulate clinical services at all levels of the 
healthcare system through a network approach, by including 
primary care, palliative care (eg, home care) and survivorship care, 
among others, in the organisational framework.
The patient journey does not begin or end in a special-
ised MDT unit: early diagnosis, quality of care for patients 
who cannot undergo surgery and the organisation of 
follow- up remain equally important challenges. Family 
doctors’ awareness and suspicion of pancreatic cancer is 
crucial for achieving early diagnosis and a subsequently 
better prognosis, and indeed, primary care has an impor-
tant parallel role to specialist services throughout the 
treatment phase and beyond.11 Outpatient palliative care 
(eg, home care, pain clinics), survivorship and rehabilita-
tion services can likewise greatly improve patients’ quality 
of life. Incorporating supportive care early in the care 
process is of special importance. To facilitate the patient 
journey, a single health professional (such as a general 
practitioner, nurse or specialist) should be designated 
as a principal contact to help patients navigate different 
levels of care and ensure effective communication.
B. Reinforcement of the internal structure of centres, care 
processes and proven expertise
Statement 8. Equip reference centres with appropriate 
infrastructures as well as material and technical resources to 
enable MDTs to effectively perform their mission.
Efficiently reorganising the internal structure of the 
centre and adopting quality care processes can affect 
patient outcomes more than merely increasing surgical 
volume. As laid out by ECCO,10 outcomes may be 
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associated, for example, with expert tumour boards, 
highly specialised resources such as intensive care units 
and molecular pathology departments, and 24/7 on- call 
surgery and specialists (including interventional radiol-
ogists and endoscopists). Such internal structures also 
influence centres’ ability to anticipate and confidently 
manage acute and sometimes life- threatening complica-
tions.
Statement 9. Capitalise on the opportunities offered by reference 
centres for developing, accumulating and applying expertise.
Centralised teams that manage highly complex diseases 
are the natural setting for developing professional 
skills. The experience acquired by providers in caring 
for patients with tumours such as pancreatic cancer—
in terms of shared utilisation of technology and expert 
knowledge—could translate into a shared benefit, influ-
encing the outcomes of patients with different profiles 
and enhancing the learning opportunities for healthcare 
professionals.
Statement 10. Staff MDT units with specialists from all disciplines 
who have a role in pancreatic cancer care.
The ECCO Essential Requirements for Quality Cancer 
Care initiative calls for specialised MDT units to include 
the core specialties of medical oncology, gastroenter-
ology/endoscopy, pathology, radiology/interventional 
radiology, surgery, nuclear medicine, radiation oncology, 
nursing and palliative care. An extended MDT should 
include professionals from fields such as anaesthesia/
intensive care, geriatric oncology, nutrition, oncology 
pharmacy, psycho- oncology, physiotherapy, genetics, and 
rehabilitation and survivorship.
Statement 11. Consider implementing formal accreditation 
systems for centres and professionals.
Accrediting centres and professionals may have a signifi-
cant impact on the reorganisation of healthcare services 
in cases where having multidisciplinary clinical units for 
hepatobiliopancreatic diseases have been identified as a 
quality criterion. At the same time, professional accred-
itation of clinical competencies for specialists in pancre-
atic diseases is also a critical element from a European 
perspective. Standardising training to the point where 
expert knowledge and skills are equivalent across coun-
tries could facilitate professional exchange and mobility, 
and benefit geographical areas with scarce or inequitably 
concentrated expertise.
C. Implementation of external assessment of quality and feedback 
performance systems
Statement 12. Establish standardised electronic health records 
systems for pancreatic cancer and maintain high-quality cancer 
registries to generate and share real-world data.
Standardised reporting with electronic health records 
can generate valuable epidemiological data. At the 
same time, cancer registries that include information on 
outcomes and/or quality measures related to pancreatic 
cancer are fundamental for illustrating the variability of 
clinical practice and understanding potential differences 
in quality between centres. Together, these systems can 
foster research, enhance transparency and help centres 
improve the quality of their services.
Statement 13. Use external data assessment to inform 
organisational changes and quality improvement strategies.
Reference centres should be defined and monitored 
according to criteria defined at a system level. Evaluation 
may be based on external clinical audits, population- 
based cancer registries, clinical follow- up registries and 
national quality programmes, and these assessments can 
drive the reorganisation of healthcare systems and treat-
ment centres, including in pancreatic cancer care. Feed-
back performance systems can complement the set of 
strategies described here.
Statement 14. Determine and report performance indicators along 
with patient and surgical volumes, to increase transparency and 
facilitate decisions on treatment centres.
Transparency around care quality and outcomes for 
providers treating patients with pancreatic cancer may 
factor into decisions about referral to the treatment centre 
or directly into patients’ preferences. Existing perfor-
mance indicators, like surgical volume and outcomes, 
should be published, even as other indicators capturing 
information on other domains of care, should be devel-
oped and validated at a national level (eg, by the cancer 
plan or healthcare system).
D. Research
Statement 15. Establish a research agenda for neglected cancers 
at the European level, using pancreatic cancer as the archetype.
Prioritisation of this area of work by the European 
Commission should create ripple effects in member 
states, enabling advances in basic as well as epidemiolog-
ical, genetic, translational, clinical and healthcare services 
research. Indeed, only by supporting a comprehensive 
research agenda can the outcomes of neglected cancers 
truly improve. Participation by patient groups in shaping 
and planning this work will be fundamental in aligning 
knowledge generation with patient needs.
Statement 16. Prioritise research streams and structures dedicated 
to prevention, risk prediction, early detection and diagnosis, and 
rapid referral for treatment.
Risk prediction, early diagnosis and appropriate treat-
ment indications in pancreatic cancer remain central 
challenges for improving survival outcomes. There are 
still large evidence gaps about which pancreatic lesions are 
pre- malignant, how high- risk groups should be defined 
and identified, which diagnostic tests are most accurate, 
and who would most benefit from screening. Likewise, 
there is an urgent need to articulate rapid referral path-
ways for patients presenting with ‘red flag’ symptoms 
in different contexts. Investments are needed in both 
data repositories (eg, biobanks, tissue banks, healthcare 
services data) and in sustained research programmes.
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Statement 17. Foster the design of collaborative research 
programmes/platforms within reference centres.
Designating reference centres at regional, national and 
international level can facilitate these centres’ leadership in 
basic, clinical and translational research as well as in profes-
sional training. Research programmes should be developed 
and carried through in collaboration with national and 
international partners, patient organisations, and other 
public and private partners with a special interest in pancre-
atic cancer, and in alignment with a European research 
agenda.
E. Optimisation of the role of patient organisations, scientific 
societies and European stakeholders
Statement 18. Engage patient organisations as equal partners in 
shaping policies based on a holistic vision of the patient journey, 
from clinical suspicion to diagnosis, treatment, palliation and 
survivor care.
Patients are the group with the most to gain from central-
ising care in highly specialised MDT units; however, they 
are not always informed of the potential for improved clin-
ical and surgical outcomes nor consulted about how such 
changes would affect them. Empowering patients to play an 
active role in the reorganisation of care models can avert 
potential problems associated with logistics (transport, 
accommodation) and economic burdens related to treat-
ment. Moreover, embedding their perspective in decisions 
about patient flows within and between care levels is the 
only way to achieve a truly patient- centred organisational 
model.
Statement 19. Empower patient representatives to take ownership 
and leadership in public debates about optimisation of healthcare 
models.
Policies denominated ‘centralisation strategies’ may not be 
well received by the public based on the concern that these 
would introduce limitations and discrimination in access to 
care. Because the most powerful advocates for patients are 
patients, survivors and their loved ones, patient groups are 
vital partners in building the political momentum neces-
sary to implement evidence- based improvements. In order 
to do so, they need to be informed and actively involved in 
public debates.
Statement 20. Develop guidelines that can help healthcare 
systems align best practices in healthcare, health services 
organisation and human resource development.
Scientific societies are uniquely situated at the nexus of 
research, practice and policy; moreover, their diverse 
membership ensures both depth and breadth to their 
expertise. These bodies can build on their experience devel-
oping clinical practice guidelines in order to set organisa-
tional specifications and define professional competencies, 
providing solid guidance for healthcare authorities, practi-
tioners and educational institutions.
Statement 21. Shape the policy environment in a way that favours 
investments in research and evidence-based care models.
This can include forming alliances and collaborations 
between major stakeholders, including patient organisations 
and scientific societies dedicated to improving neglected 
cancer care.
Statement 22. Organise national and international awareness 
campaigns with a special focus on prevention and early diagnosis.
Awareness campaigns can serve a dual purpose in the 
field of pancreatic cancer: (a) fostering people’s recog-
nition of risk factors and early signs and symptoms of the 
disease in order to favour better primary and secondary 
prevention, and (b) building public support for prior-
itising this disease at the health system level.
CONCLUSIONS
Scientific evidence supports the contention that substan-
tial improvements can be achieved in patient outcomes 
by organising pancreatic cancer care around state- of- 
the- art reference centres, staffed by expert MDTs. This 
organisational model requires a specific care framework 
that encompasses all levels of healthcare services, incor-
porating quality criteria and performance assessments. 
While such measures can produce tangible benefits for 
patients, the biggest promise for improving outcomes lies 
in research, especially on prevention, risk prediction and 
early detection. Patient organisations, scientific societies 
and advocacy groups play a crucial role in the develop-
ment of patient- centred policies aligned with current 
research evidence.
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